Please assess the completion status of the following clinical trial:

Trial Title: Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women ≥18 years old who are recipients of an allogeneic bone marrow, cord blood or peripheral blood stem cell transplant. (There will be no restrictions based upon underlying disease, donor source, degree of human leukocyte antigen (HLA) match, intensity of pre-transplant conditioning regimen or use of prior donor lymphocyte infusion(s).)~2. Chronic GVHD that is confirmed by clinical assessment and/or biopsy.~3. Either steroid-refractory or steroid-dependent cGVHD.~4. Karnofsky performance status ≥ 60.~Exclusion Criteria:~1. History of treatment with a tyrosine kinase inhibitor (eg, imatinib) or other moderate-to-significant Cyclophilin A4 inhibitor within 2 weeks of enrollment.~2. Renal insufficiency as follows: creatinine \> 2.5 mg/deciliters (dL) or Creatinine Clearance \< 30 ml/min.~3. Hepatic insufficiency as follows: serum bilirubin \>3 mg/dL or transaminitis \>3x upper limit of normal (ULN) (unless deemed due to GVHD).~4. History of cardiac dysrhythmias or known cardiovascular disease without formal Cardiology clearance.~5. History of cerebro-vascular accident or intracranial hemorrhage within 6 months prior to enrollment.~6. History of non-intracranial hemorrhage and/or coagulopathy without formal Coagulation clearance.~7. Uncontrolled infections not responsive to antibiotics, anti-viral medicines, or anti-fungal medicines; or infection requiring systemic treatment that was completed ≤14 days before enrollment.~8. History of other hematologic malignancy.~9. History of human immunodeficiency virus (HIV).~10. History of active hepatitis B virus (HBV) or hepatitis C virus (HCV) without formal Infectious Disease clearance.~11. Patients incapable of complying with routine follow up schedule or unable to be compliant with study therapy.~12. Active or within 3 months use of prohibited medications or substances (e.g., illicit drugs).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibrutinib plus Rituximab (Type: EXPERIMENTAL): Rituximab~\*375 milligrams (mg) per meter squared intravenous infusion weekly for 4 (may repeat 8 weeks after initial therapy, if suboptimal response)~Ibrutinib~* 420 mg (140 mg capsule x3) by mouth daily~* May be given beyond 3-6 months (for maintenance).

Based on this trial design, predict the completion outcome and termination type (if applicable).